Navigation Links
Rosetta Genomics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/5/2008

REHOVOT, Israel and JERSEY CITY, New Jersey, November 5 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader in the development of microRNA-based diagnostics, announced today it will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Wednesday, November 10 at The New York Palace Hotel in New York City.

About MicroRNA

MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on c
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2007 Healthcare Conference
2. Rosetta Genomics Strengthens Senior Management in Preparation for its First Commercial Launch of microRNA-Based Diagnostic Products in 2008
3. NeoGenomics Schedules Its Q3 2008 Earnings Release for November 6, 2008
4. UC San Diego to lead nationwide program in pharmacogenomics
5. NeoGenomics to Present at the Noble Financial Equity Conference
6. NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008
7. AutoGenomics, Inc. Files Registration Statement for Initial Public Offering
8. AutoGenomics INFINITI Analyzer Receives Artistic Design Award
9. AutoGenomics Receives a Key European Patent for HPV Detection
10. Genomics of Cardiovascular Disease: Current Clinical Applications
11. Navigenics Proposes Standards for Personal Genomics Services, Coupled With Prospective Outcomes Studies, to Safeguard Consumers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... first year follow a set of predictable steps ... first words. However, previous research had not addressed ... hearing and deaf infants. Now, University of Missouri ... by infants, ability to hear their own babbling. ... cochlear implants to help correct their hearing soon ...
(Date:9/23/2014)... PITTSBURGH, PA (PRWEB) September 23, 2014 "The ... and infection control," said an inventor from Sacramento, Ca.. "Call ... patient bedding or left hanging on the IV pole out ... patients have the nurse call device whenever they need it, ... CADDY to effectively position the nurse call device within easy ...
(Date:9/23/2014)... CONVENE PATHWAYS TO PREVENTION WORKSHOP: ROLE OF OPIOIDS IN ... , The National Institutes of Health is convening a ... evidence on the long-term effectiveness and potential risks of ... the nation,s top experts in the field of pain ... as key NIH scientists who focus on pain related ...
(Date:9/23/2014)... September 23, 2014 World of Home ... philanthropic support. Most recently, the gym has been raising ... Fitness program. Throughout the year, World of Home Fitness ... charitable causes. , Over the summer, World of Home ... Through their Ageless Fitness program, participants helped feed seniors ...
(Date:9/23/2014)... San Diego, CA (PRWEB) September 23, 2014 ... website daily regarding all the latest information from the ... announced on September 5, that its Private Label Jalapeno ... glass and small stones. Publix Jalapeno Bagels ... in the bakery department. , Taking into consideration ...
Breaking Medicine News(10 mins):Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:World of Home Fitness Supports Meals on Wheels 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... Aug. 31 Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that ... Sept. 10, 2009, at 2:40 p.m. EDT. Alan Levin, Chief Financial Officer ... The presentation will be webcast live and can be accessed from ... , , About Endo , ...
... , , BERWYN, Pa., Aug. 31 ... service multinational clinical research organization (CRO) conducting studies in over 30 ... today announced that on August 25, 2009, it received a letter ... its Form 10-Q for the period ended June 30, 2009, NASDAQ ...
... , , SCOTTSDALE, ... today announced that, at the Company,s 2009 Annual Meeting of Stockholders, ... an overwhelming majority all of the Company,s nominees to the board ... 63,725,589, representing approximately 56% of the 114,007,240 shares outstanding as of ...
... study, blood-thinning drug best for those at highest risk of ... patients, or those with a prior history of stroke, are ... treat atrial fibrillation, a common heart rhythm disorder, a new ... also say the drug is especially beneficial for patients with ...
... Aug. 31 (HealthDay News) -- Walk-in retail clinics staffed by ... study has found. , Writing in the Sept. 1 issue ... Dr. Ateev Mehrotra said that retail clinics -- which are ... and other retail chain stores such as Target and Wal-Mart ...
... patients choose where to get their care based on how ... at Fox Chase Cancer Center have recently documented a growing ... at high volume centers, which are generally located in metropolitan ... a study published in the Journal of Clinical Oncology ...
Cached Medicine News:Health News:Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 2Health News:Encorium Receives NASDAQ Deficiency Letter Regarding Stockholders' Equity 2Health News:Encorium Receives NASDAQ Deficiency Letter Regarding Stockholders' Equity 3Health News:Healthcare Trust of America, Inc. Announces Results of 2009 Annual Meeting of Stockholders 2Health News:Healthcare Trust of America, Inc. Announces Results of 2009 Annual Meeting of Stockholders 3Health News:Oldest Heart Patients May Get Most From Warfarin 2Health News:Retail Medical Clinics Offer Quality Care: Study 2Health News:Retail Medical Clinics Offer Quality Care: Study 3Health News:Does the distance a patient has to travel affect where they choose to get their care? 2
(Date:9/23/2014)... , Sept. 23, 2014  SiteOne Therapeutics Inc. ... equity financing. Led by Sears Capital Management and Biobrit ... Joe Zakrzewski , the $1.5 million financing positions SiteOne ... for pain and to further develop its technology platform ... indications. In conjunction with the financing, ...
(Date:9/23/2014)...   COTA, Inc. today announced it has ... A funding round led by Horizon Healthcare Services, Inc. ... big data platform designed by practicing oncologists to deliver ... care in support of healthcare,s new value-based reimbursement model. ... of the COTA platform, hire biostatisticians, outcome analysts, data ...
(Date:9/23/2014)... , Sept. 23, 2014  While proton therapy recently began in the ... Ashya King , another case in the United States ... a young boy who was given just days to live now looks ... Logan Green of Arizona complained of a ... of medical treatments that will conclude Sept. 23, when he completes ...
Breaking Medicine Technology:SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 45-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 25-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 35-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 4
... Pervasis Therapeutics, Inc. today announced that it has ... government,s Qualifying Therapeutic Discovery Project, which provides tax credits ... produce new therapies, reduce long-term health care costs, or ... next 30 years.   Pervasis is a ...
... 4, 2010 The physicians of Westside Medical Associates ... Beverly Hills , California have announced the results of a ... CT scans save lives.  According to Drs. Norman ... Medical Imaging, this study should once and for all settle ...
Cached Medicine Technology:Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project 2Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project 3Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project 4Annual CT Lung Screening Saves Lives 2
... Screen ELISA test system is a qualitative screening ... human sera. When performed according to the directional ... all ANAs commonly tested for, such as those ... SSA, SSB, and Scl-70. The test is also ...
... Immuno Concepts manufactures slides that are compatible ... to decrease the number of pipetting steps ... sample dilutions on the slides. Ask Immuno ... and these slides. These slide formats are ...
... patented HEp-2 cell line that has been ... SS-A/Ro autoantibodies, without affecting the other ANA ... published worldwide on the HEp-2000 ANA substrate, ... when used in place of standard HEp-2 ...
... ENA assays can be used to ... antibodies, which are associated with various ... lupus erythematosus (Lupus), Sjgren's syndrome, mixed ... scleroderma, polymyositis, dermatomyositis, and Raynaud's phenomenon. ...
Medicine Products: